Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
about
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemiaColony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemiaPrognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisWilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyGene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaDiagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 casesAdult acute erythroleukemia: an analysis of 91 patients treated at a single institutionSequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaVarious distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialNelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyEfficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual diseaseEffect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center StudyEarly reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.Epigenetic therapies in MDS and AMLPrimary refractory acute myeloid leukaemia - in search of better definitions and therapies.Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaPrognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy.Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemiaPhase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspensionClinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.Smoking adversely affects survival in acute myeloid leukemia patientsManagement of acute myelogenous leukemia in the elderly.Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraThe role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.
P2860
Q24202698-C72CAF9B-544C-4DB7-BE40-5756F7643F93Q24234458-5AA0E038-45BA-4B0C-90B4-CF88E7C52B36Q26771740-B1720E1C-5BB9-47A6-BBFD-EA01BC6CF725Q27851436-097FD150-2E49-4644-BC7B-4622E324AF0BQ27851460-53CC9605-9681-4CB5-8F74-EA5436319927Q27851621-6FB7D56C-8019-4732-B77F-977B954F884CQ27851713-6E0C2107-25ED-4759-A547-29A79C448418Q28143195-751D65A1-8AA7-4538-930D-13F81B27E4FFQ28258018-49DC75F2-42E7-4DD3-9C44-1B258C6D00F9Q30497200-0EA4C7E5-9DA3-486C-8EAD-FE6D0550E278Q33264716-971EF679-1C2C-4324-8BB6-B4490C8BC179Q33350688-6927FC55-58D0-47CF-9B1A-29A2CA606350Q33374461-91BB70D8-7E4D-47F5-A8E1-03AD8F3356D9Q33380148-9DC360F7-C76A-421D-9B0A-09C8199BD556Q33403865-5149CEB1-69C6-4C44-8459-AF61AFD76012Q33417145-17E8FFF3-B9EB-4833-BBA5-8EEB9484C299Q33608880-B072814B-98F0-4A77-8176-54C2D1A65696Q33770347-26C399F2-AD22-4D37-AAA0-EA98F133F2F6Q33829117-904E2F24-FEB1-475D-978F-ACF2A421A5A5Q33863567-A68FBE02-7A58-46E2-B774-D7154892F60DQ33877213-ADD1DCC2-AFA1-4E7F-9AC9-C9F14D01E844Q34011740-7F58A28A-4827-4748-8CE1-688B6AA42423Q34069811-E623646D-EF2C-4E41-8498-5B6ACD9F74C1Q34124919-FCD5CDF3-B6C4-4B73-935C-7C41D15AA3D2Q34197535-6F1DC9D7-9819-4990-9AFA-180E3AA73A0BQ34285937-63FB24D9-6B96-4378-AE4D-B84255A8BC12Q34310859-DC2735FA-DDB5-41FC-83FD-8EE35EA06BA9Q34358512-06BAE671-7C08-4F39-9BB6-35AE10DB3925Q34643306-C89E2C99-DF57-4053-9BA7-DFCBE2308F63Q34810797-B7000166-07F5-40C6-8FE4-71DF5410B762Q34816246-28E2C1D3-8704-46FD-81BC-10A4DF547381Q34951945-A2526C43-0A01-48C6-9B49-42746C117E2AQ34983843-F50A947E-AA31-4740-9B5D-39D7D7615D0FQ35256120-024CE49C-F6DE-4B57-BD68-7041C3D696ADQ35265946-7BF5A147-0E40-4895-B33C-53F2215A86A5Q35361598-F07A228C-C1D5-4044-99FF-107EA9C552D6Q35449042-12A74AB3-223C-465F-8909-4887CFF6FF2AQ35599067-0F24D35B-F734-40F2-9399-2F92AAE35EFEQ35640734-1EE758AA-768C-4B87-96D4-483466F80CEEQ35643005-B878ADB2-5C39-4CF4-80F0-FCC737860689
P2860
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Report of the National Cancer ...... nse in acute myeloid leukemia.
@en
Report of the National Cancer ...... nse in acute myeloid leukemia.
@nl
type
label
Report of the National Cancer ...... nse in acute myeloid leukemia.
@en
Report of the National Cancer ...... nse in acute myeloid leukemia.
@nl
prefLabel
Report of the National Cancer ...... nse in acute myeloid leukemia.
@en
Report of the National Cancer ...... nse in acute myeloid leukemia.
@nl
P2093
P921
P356
P1476
Report of the National Cancer ...... nse in acute myeloid leukemia.
@en
P2093
B D Cheson
C A Schiffer
J M Bennett
M J Keating
M R Grever
P A Cassileth
R Brunning
P304
P356
10.1200/JCO.1990.8.5.813
P407
P577
1990-05-01T00:00:00Z